{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T12:48:31Z","timestamp":1784378911654,"version":"3.55.0"},"reference-count":50,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Der Einsatz von Psychedelika in Psychiatrie und Psychotherapie wird vertieft\n                    wissenschaftlich untersucht, national wie international zunehmend fachlich und\n                    gesellschaftlich diskutiert sowie international bereits teilweise klinisch\n                    praktiziert. Der Artikel bietet eine kurze Standortbestimmung auch hinsichtlich\n                    Evidenzlage, kritischer klinischer Fragen und Risiken. Rechtliche, ethische und\n                    \u00f6konomische Aspekte werden beleuchtet, therapeutische Qualifikationen m\u00f6glicher\n                    Anwender werden diskutiert und es wird unter Benennung noch aktueller\n                    Herausforderungen auf eine m\u00f6gliche klinisch-psychiatrische Einbettung\n                    eingegangen. Insgesamt wird besprochen, unter welchen Voraussetzungen in der\n                    Anwendung von Psychedelika ein gewisses Potenzial hinsichtlich Erweiterung des\n                    Behandlungsspektrums psychischer Erkrankungen liegen k\u00f6nnte, insb. angesichts\n                    auch unter derzeitigen Methoden h\u00e4ufig therapieresistenter und chronischer\n                    Verl\u00e4ufe. Auf jeden Fall w\u00e4ren wesentliche grunds\u00e4tzliche Fragen vor einer\n                    eventuellen Einf\u00fchrung zu kl\u00e4ren. <\/jats:p>","DOI":"10.1055\/a-2453-0910","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T18:56:02Z","timestamp":1734029762000},"page":"343-351","source":"Crossref","is-referenced-by-count":4,"title":["Psychedelika in der Psychiatrie: eine offene Debatte"],"prefix":"10.1055","volume":"93","author":[{"given":"Uwe","family":"Herwig","sequence":"additional","affiliation":[{"name":"Akademisches Lehrkrankenhaus Universit\u00e4t Konstanz, Zentrum f\u00fcr\n                    Psychiatrie Reichenau, Reichenau, Germany"},{"name":"Klinik f\u00fcr Psychiatrie, Psychotherapie und\n                    Psychosomatik, Psychiatrische Universit\u00e4tsklinik Z\u00fcrich, Z\u00fcrich,\n                    Switzerland"},{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie III,\n                    Universit\u00e4t Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Schnell","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie Universit\u00e4tsmedizin\n                    G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Daumann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie, Universit\u00e4t\n                    zu K\u00f6ln, K\u00f6ln, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jungaberle","sequence":"additional","affiliation":[{"name":"MIND Foundation, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Koller","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie, LMU, M\u00fcnchen,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Julia","family":"Mertens","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Molekulares Neuroimaging, Zentralinstitut f\u00fcr Seelische\n                    Gesundheit, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5792-3987","authenticated-orcid":false,"given":"Stefan","family":"Borgwardt","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Schleswig Holstein Campus L\u00fcbeck,\n                    Klinik f\u00fcr Psychiatrie und Psychotherapie, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and Psychedelic-Assisted Psychotherapy","volume":"177","author":"C M Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/a-1981-3152","article-title":"Psychedelika in der Psychiatrie \u2013 Entwicklungen und die Stellung in Deutschland\n                    [Psychedelics in Psychiatry \u2013 Development and Current State in Germany]","volume":"91","author":"U Herwig","year":"2023","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1176\/appi.ajp.20230172","article-title":"Psychedelics as Transformative Therapeutics","volume":"180","author":"B L Roth","year":"2023","journal-title":"Am J Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"R Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major\n                    Depression","volume":"387","author":"G M Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMcibr2213109","article-title":"Translational Challenges in Psychedelic Medicine","volume":"388","author":"R L Carhart-Harris","year":"2023","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for\n                    depression","volume":"28","author":"R E Daws","year":"2022","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","article-title":"Psychedelics reopen the social reward learning critical period","volume":"618","author":"R Nardou","year":"2023","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind,\n                    placebo-controlled phase 3 study","volume":"27","author":"J M Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label\n                    feasibility study","author":"S K Peck","year":"2023","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1038\/d41586-022-02868-5","article-title":"Psychedelic medicine faces the acid test","volume":"609","author":"H Brody","year":"2022","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a\n                    randomized clinical trial","volume":"78","author":"A K Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231167848","article-title":"A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin\n                    therapy versus escitalopram treatment for depression","author":"B Weiss","year":"2023","journal-title":"J Psychopharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant\n                    SSRI medication","author":"G M Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A\n                    placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"R von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs\n                    Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A\n                    Randomized Clinical Trial","volume":"79","author":"M P Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"T D McClure-Begley","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","article-title":"Psychedelic therapy for depressive symptoms: A systematic review and\n                    meta-analysis","volume":"322","author":"K Ko","year":"2023","journal-title":"J Affect Disord"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-02093-8","article-title":"Australia to prescribe MDMA and psilocybin for PTSD and depression in world\n                    first","volume":"619","author":"R Haridy","year":"2023","journal-title":"Nature"},{"key":"ref22","first-page":"171","article-title":"Klassische Psychedelika als Therapeutika in der Psychiatrie","volume":"27","author":"L Mertens","year":"2020","journal-title":"Psychopharmakotherapie"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00115-021-01255-1","article-title":"Sind Psychedelika schnell wirksame Antidepressiva? [Are psychedelics fast acting\n                    antidepressant agents?]","volume":"93","author":"G Gr\u00fcnder","year":"2022","journal-title":"Nervenarzt"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/JPR.S360733","article-title":"Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the\n                    Literature","volume":"15","author":"S J Drozdz","year":"2022","journal-title":"J Pain Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.1995","article-title":"MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A\n                    Systematic Review With Meta-Analysis","volume":"62","author":"K W Smith","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic Drug Legislative Reform and Legalization in the US","volume":"80","author":"J S Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: From anecdotes and misinformation to systematic\n                    science","volume":"36","author":"A K Schlag","year":"2022","journal-title":"J Psychopharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","article-title":"Is LSD toxic?","volume":"284","author":"D E Nichols","year":"2018","journal-title":"Forensic Sci Int"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"D E Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria\n                    decision analysis","volume":"376","author":"D J Nutt","year":"2010","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0269881121996863","article-title":"Associations between lifetime classic psychedelic use and markers of physical\n                    health","volume":"35","author":"O Simonsson","year":"2021","journal-title":"J Psychopharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","article-title":"Maintenance ketamine treatment for depression: a systematic review of efficacy,\n                    safety, and tolerability","volume":"9","author":"S Y Smith-Apeldoorn","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"174156","DOI":"10.1016\/j.ejphar.2021.174156","article-title":"Ecstasy (3,4-methylenedioxymethamphetamine): Cardiovascular effects and\n                    mechanisms","volume":"903","author":"D A Fonseca","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"113894","DOI":"10.1016\/j.expneurol.2021.113894","article-title":"Neurotoxicity of MDMA: Main effects and mechanisms","volume":"347","author":"G Costa","year":"2022","journal-title":"Exp Neurol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00213-022-06086-9","article-title":"MDMA and memory, addiction, and depression: dose-effect analysis","volume":"239","author":"M M Pantoni","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of\n                    Psilocybin for Treatment-Resistant Depression","volume":"8","author":"L Roseman","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"appiajp20221043","DOI":"10.1176\/appi.ajp.20221043","article-title":"Must Psilocybin Always \"Assist Psychotherapy\"?","author":"G M Goodwin","year":"2023","journal-title":"Am J Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/02791072.2022.2054746","article-title":"Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and\n                    Strategies for Optimizing Experiences","volume":"55","author":"L Shaw","year":"2023","journal-title":"J Psychoactive Drugs"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and\n                    suicidality in the United States adult population","volume":"29","author":"P S Hendricks","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","article-title":"Studying Harms Is Key to Improving Psychedelic-Assisted Therapy-Participants\n                    Call for Changes to Research Landscape","volume":"80","author":"S McNamee","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: safety and ethical concerns","volume":"7","author":"B T Anderson","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","article-title":"Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic\n                    Hallucinogens. Identification of a New Therapeutic Class: Entactogens","volume":"18","author":"D E Nichols","year":"1986","journal-title":"Journal of Psychoactive Drugs"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","article-title":"Preparing for the Bursting of the Psychedelic Hype Bubble","volume":"79","author":"D B Yaden","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamapsychiatry.2021.3972","article-title":"The Rapid Rise in Investment in Psychedelics\u2014Cart Before the Horse","volume":"79","author":"J Phelps","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0022167817711304","article-title":"Developing guidelines and competencies for the training of psychedelic\n                    therapists","volume":"57","author":"J Phelps","year":"2017","journal-title":"J Humanist Psychol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1020505","DOI":"10.3389\/fpsyt.2022.1020505","article-title":"Lower-dose psycholytic therapy \u2013 A neglected approach","volume":"13","author":"T Passie","year":"2022","journal-title":"Front Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label\n                    feasibility study","author":"S K Peck","year":"2023","journal-title":"Nat Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1178529","DOI":"10.3389\/fpsyt.2023.1178529","article-title":"Safety, tolerability, and clinical and neural effects of single-dose psilocybin\n                    in obsessive-compulsive disorder: protocol for a randomized, double-blind,\n                    placebo-controlled, non-crossover trial","volume":"14","author":"TH W Ching","year":"2023","journal-title":"Front Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11920-022-01363-y","article-title":"The Emerging Field of Psychedelic Psychotherapy","volume":"24","author":"G S Barber","year":"2022","journal-title":"Curr Psychiatry Rep"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.neubiorev.2022.104793","article-title":"Pharmacological, neural, and psychological mechanisms underlying psychedelics: A\n                    critical review","volume":"140","author":"M van Elk","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/a-1486-7386","article-title":"The Potential Role of Psychedelic Drugs in Mental Health Care of the Future","volume":"54","author":"G Gr\u00fcnder","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291723001411","article-title":"Cost-effectiveness of psilocybin-assisted therapy for severe depression:\n                    exploratory findings from a decision analytic model","author":"P McCrone","year":"2023","journal-title":"Psychol Med"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2453-0910.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:40:32Z","timestamp":1757544032000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2453-0910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":50,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2025,9,10]]},"published-print":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2453-0910","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}